By WSJ Staff
Apple $(AAPL)$: The company's net income beat expectations, despite iPhone sales falling in the crucial December quarter. Shares climbed more than 3% in premarket trading.
Intel $(INTC)$: The chip-maker reported a smaller-than-expected decline in quarterly sales, alongside a gloomy outlook. The stock rose almost 2% premarket.
Visa (V): The credit-card company's earnings and revenue outstripped estimates, with Visa citing strong spending during the holiday season. The stock gained 2% before the opening bell.
Vertex Pharmaceuticals $(VRTX)$: Shares in the biopharmaceutical company shot up almost 10% offhours after the Food and Drug Administration approved Vertex's oral non-opioid pain medication, Journavx.
Samsung (KR:005930): The world's largest maker of memory chips and smartphones forecast limited earnings growth in this quarter due to weakening profits in its core semiconductor sector. Samsung shares fell 2.4% in South Korea.
Novartis (CH:NOVN, NVS): The pharmaceutical company forecast further profit and sales growth this year, after beating fourth-quarter expectations. Shares rose 3.5% in Switzerland.
AbbVie $(ABBV)$, Chevron $(CVX)$, Colgate-Palmolive $(CL)$ and Exxon Mobil $(XOM)$ are scheduled to report earnings before U.S. markets open today.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
January 31, 2025 04:59 ET (09:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.